Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention

NAEnrolling by invitationINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Postoperative Nausea and VomitingGynecologic Surgical ProceduresLaparoscopy
Interventions
DRUG

fosaprepitant

"The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.~In the experimental group, the subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered."

DRUG

normal saline

"On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes."

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER